Clinical benefit from EGFR-TKI plus ginsenoside Rg3 in patients with advanced non-small cell lung cancer harboring EGFR active mutation

Abstract

// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Yan Li1, *, Yanmei Wang1, *, Kai Niu1, Xiewan Chen2, Liqin Xia1, Dingxi Lu2, Rui Kong1, Zhengtang Chen1, Yuzhong Duan1, Jianguo Sun1 1Department of Oncology, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China 2Medical English Department, College of Basic Medicine, Third Military Medical University, Chongqing, 400038, China *These authors have contributed equally to this work Correspondence to: Yuzhong Duan, email: cqxqyy@foxmail.com Jianguo Sun, email: sunjg09@aliyun.com Keywords: advanced NSCLC, EGFR active mutation, targeted molecular therapy, ginsenoside Rg3, angiogenesis Received: April 11, 2016 Accepted: August 25, 2016 Published: September 16, 2016